Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00829179 · ClinicalTrials.gov registry record · Phase 3
Role of RhuMab-E25 in Reducing Exhaled Nitric Oxide (NO) in Allergic Asthma
A Phase 3 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 3
- Development phase
- 20
- Enrollment target
NCT00829179 is a Phase 3 study that has completed, run by Duke University. The registered enrollment target is 20 participants.
The verdict
NCT00829179, a Phase 3 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 20 participants
- Enrollment target
Study Summary
A single center pilot study to determine the protective effects of RhuMAB-E25 on airway physiology and biology in allergic asthmatics that undergo bronchoprovocation with methacholine. The primary study objective determines the protective impact of RhuMAB-E25 on airway inflammation as reflected in exhaled nitric oxide (NO) levels in allergic asthmatics. The secondary objective determines the protective effect of rhuMAB E25 against airway bronchoconstriction as reflected in the Provocative Concentration of methacholine to cause a 20% fall in FEV1(PC20) with methacholine challenge testing.
Interventions
- DRUG RhuMab-E25
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2002-10 |
| Est. Completion | 2004-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00829179
The ClinicalTrials.gov registry entry for NCT00829179 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RhuMab-E25 is the first listed.
NCT00829179 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00829179 about?
NCT00829179 is a clinical study titled "Role of RhuMab-E25 in Reducing Exhaled Nitric Oxide (NO) in Allergic Asthma". A single center pilot study to determine the protective effects of RhuMAB-E25 on airway physiology and biology in allergic asthmatics that undergo bronchoprovocation with methacholine. The primary study objective determines the protective impact of RhuMAB-E25 on airway inflammation as reflected in ...
What is the current status of trial NCT00829179?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 20 participants. The study started on 2002-10. Estimated completion is 2004-07.
What interventions are being tested in trial NCT00829179?
The interventions under investigation include: RhuMab-E25 (DRUG).
Who is sponsoring clinical trial NCT00829179?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.